Reported Severe Hypersensitivity Reactions after Intravenous Iron Administration in the European Economic Area (EEA) Before and After Implementation of Risk Minimization Measures
Authors:
Open Access
- 3 October 2019
- journal article
- research article
- Published by Springer Nature in Drug Safety
- Vol. 43 (1) , 35-43
Abstract
Introduction Severe hypersensitivity reactions (HSRs) such as anaphylaxis are of great clinical concern because of their life-threatening potential. The adverse events attributable to intravenous iron products include HSRs. An investigation by the European Medicines Agency presented in late 2013 resulted in the implementation of risk minimization measures (RMMs). Objective This study evaluated the number of severe HSRs reported for intravenous iron substances related to exposure for the 4-year periods before and after this implementation. Methods This was a retrospective pharmacoepidemiologic study with a case-population design. We obtained information from the safety surveillance database EudraVigilance on spontaneously reported severe HSRs using the Medical Dictionary for Regulatory Activities preferred terms “anaphylactic reaction/shock” and “anaphylactoid reaction/shock”. Exposure was estimated using IQVIA MIDAS sales data in European economic area countries. Results Reporting rates for individual products were heterogenous, and the implementation of RMMs appeared to have no clear impact. Reporting rates remained low for the full study period for iron sucrose (0.03–0.20) and ferric gluconate (0.02–0.14) and were higher at the beginning and lower at the end of the study period for ferric carboxymaltose (1.47–0.18). No clear trend was detected for iron dextran (range 0.22–2.80) and iron (III) isomaltoside 1000 (range 0–7.94). Conclusions Future research is needed to investigate whether the wide variability in reporting rates for severe HSRs associated with these intravenous iron products are due to potential differences in the safety profiles of these substances.Keywords
Funding Information
- Vifor Pharma International AG
This publication has 17 references indexed in Scilit:
- Comparison of hypersensitivity reactions of intravenous iron: iron isomaltoside‐1000 (Monofer ® ) versus ferric carboxy‐maltose (Ferinject ® ). A single center, cohort studyBritish Journal of Clinical Pharmacology, 2018
- Intravenous Irons: From Basic Science to Clinical PracticePharmaceuticals, 2018
- Global, regional, and national incidence, prevalence, and years lived with disability for 328 diseases and injuries for 195 countries, 1990–2016: a systematic analysis for the Global Burden of Disease Study 2016The Lancet, 2017
- Iron deficiency across chronic inflammatory conditions: International expert opinion on definition, diagnosis, and managementAmerican Journal of Hematology, 2017
- Drug‐specific hypophosphatemia and hypersensitivity reactions following different intravenous iron infusionsBritish Journal of Clinical Pharmacology, 2017
- Comparative Risk of Anaphylactic Reactions Associated With Intravenous Iron ProductsJAMA, 2015
- Direct Comparison of the Safety and Efficacy of Ferric Carboxymaltose versus Iron Dextran in Patients with Iron Deficiency AnemiaAnemia, 2013
- ForewordKidney International Supplements, 2012
- Differences in spontaneously reported hypersensitivity and serious adverse events for intravenous iron preparations: comparison of Europe and North AmericaArzneimittelforschung, 2011
- Revised nomenclature for allergy for global use: Report of the Nomenclature Review Committee of the World Allergy Organization, October 2003Journal of Allergy and Clinical Immunology, 2004